ES2945220T3 - Indazol carboxamidas como inhibidores de cinasas - Google Patents

Indazol carboxamidas como inhibidores de cinasas Download PDF

Info

Publication number
ES2945220T3
ES2945220T3 ES19779242T ES19779242T ES2945220T3 ES 2945220 T3 ES2945220 T3 ES 2945220T3 ES 19779242 T ES19779242 T ES 19779242T ES 19779242 T ES19779242 T ES 19779242T ES 2945220 T3 ES2945220 T3 ES 2945220T3
Authority
ES
Spain
Prior art keywords
methyl
indazol
alkyl
carboxamide
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19779242T
Other languages
English (en)
Spanish (es)
Inventor
Junqing Guo
Carolyn Diane Dzierba
Amy C Hart
John E Macor
William J Pitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2945220T3 publication Critical patent/ES2945220T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES19779242T 2018-09-13 2019-09-12 Indazol carboxamidas como inhibidores de cinasas Active ES2945220T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730611P 2018-09-13 2018-09-13
PCT/US2019/050721 WO2020056074A1 (en) 2018-09-13 2019-09-12 Indazole carboxamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2945220T3 true ES2945220T3 (es) 2023-06-29

Family

ID=68073172

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19779242T Active ES2945220T3 (es) 2018-09-13 2019-09-12 Indazol carboxamidas como inhibidores de cinasas

Country Status (14)

Country Link
US (1) US12084426B2 (enExample)
EP (1) EP3849969B1 (enExample)
JP (1) JP7434294B2 (enExample)
KR (1) KR102793119B1 (enExample)
CN (1) CN112673001B (enExample)
AU (1) AU2019339355A1 (enExample)
BR (1) BR112021004310A2 (enExample)
CA (1) CA3112519A1 (enExample)
EA (1) EA202190759A1 (enExample)
ES (1) ES2945220T3 (enExample)
IL (1) IL281371A (enExample)
MX (1) MX2021002617A (enExample)
SG (1) SG11202102406XA (enExample)
WO (1) WO2020056074A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089442A1 (en) 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
MX2020007531A (es) 2018-01-26 2020-09-09 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa.
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2020056072A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
MX2022003769A (es) * 2019-10-03 2022-04-20 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas.
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
WO2023119210A1 (ko) 2021-12-24 2023-06-29 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
RU2418797C2 (ru) 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR20130077390A (ko) 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
SG10201701649YA (en) 2012-02-21 2017-04-27 Acraf 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
AU2013224313B2 (en) 2012-02-21 2017-03-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
EP3463355B1 (en) 2016-05-26 2024-08-28 Sonic Master Limited Modulators of dux4 for regulation of muscle function
MA46453A (fr) 2016-10-07 2019-08-14 Bristol Myers Squibb Co Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
WO2019089442A1 (en) 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
MX2020007531A (es) 2018-01-26 2020-09-09 Bristol Myers Squibb Co Aminopirrolotriazinas como inhibidores de cinasa.
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2020056072A1 (en) 2018-09-13 2020-03-19 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
MX2022003769A (es) 2019-10-03 2022-04-20 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas.

Also Published As

Publication number Publication date
MX2021002617A (es) 2021-05-12
EA202190759A1 (ru) 2021-06-17
CA3112519A1 (en) 2020-03-19
AU2019339355A1 (en) 2021-05-13
WO2020056074A1 (en) 2020-03-19
US12084426B2 (en) 2024-09-10
KR20210060516A (ko) 2021-05-26
EP3849969A1 (en) 2021-07-21
KR102793119B1 (ko) 2025-04-07
IL281371A (en) 2021-04-29
EP3849969B1 (en) 2023-04-19
BR112021004310A2 (pt) 2021-05-25
JP7434294B2 (ja) 2024-02-20
US20210309633A1 (en) 2021-10-07
SG11202102406XA (en) 2021-04-29
CN112673001B (zh) 2024-06-25
CN112673001A (zh) 2021-04-16
JP2022501334A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
ES2945220T3 (es) Indazol carboxamidas como inhibidores de cinasas
ES2902676T3 (es) Aminotriazolopiridinas como inhibidores de cinasa
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
ES2905948T3 (es) Aminoimidazopiridazinas como inhibidores de cinasa
ES2936481T3 (es) 1H-Indazol-carboxamidas como inhibidores de la proteína cinasa 1 que interactúa con el receptor (RIPK1)
CN107406426A (zh) 作为rock抑制剂的环状脲类
US10301306B2 (en) Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
ES2969756T3 (es) Indazol carboxamidas como inhibidores de cinasas
CA3083061A1 (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
CN110869361A (zh) 用于治疗心力衰竭的rock的五元氨基杂环和5,6元或6,6元双环氨基杂环抑制剂
CN108341819B (zh) 磷酸二酯酶抑制剂及其用途
CN112752757B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
JP2022547729A (ja) 自己免疫疾患を治療するためのピペリジニルアミン化合物